At a glance
ClinicalIndex Comparison RecordN/ACompleted· 42 enrolled
Drug / intervention
Rifaximin +1 moredrug
Likely dose
Rifaximin 550mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Rifaximin on Driving Performance, Psychometric Test Performance and Quality of Life in Cirrhotic Patients With Minimal Hepatic Encephalopathy: Randomized, Double-blind, Placebo-controlled Trial.
Hunter Holmes Mcguire Veteran Affairs Medical Center·interventional·Posted Sep 24, 2007·Updated Dec 17, 2020
In Brief
A clinical study evaluating Rifaximin and placebo for Hepatic Encephalopathy. Completed, enrolled 42 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether alteration of gut flora with rifaximin can lead to improvement in driving performance, psychometric test performance, and quality of life in patients with minimal hepatic encephalopathy (MHE) and cirrhosis in a randomized, blinded, placebo-controlled trial.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatic Encephalopathy
CountriesUnited States
CollaboratorsBausch Health Americas, Inc.
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2007
Enrollment StartOct 2007
Primary CompletionApr 2010
Study CompletionMay 2010
TodayJul 2026
First PostedSep 24, 2007
Enrollment StartOct 1, 2007
Primary CompletionApr 1, 2010
Study CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 18.8 years ago
Interventions
Rifaximindrug
550mg BID rifaximin for 8 weeks
placebodrug
same as the experimental arm